Castleman joined Isis’ Board of Directors in June 2013. Castleman is President and Chief Executive Officer of Syntiro Healthcare Services, Inc., currently a health care investment company, having recently sold its operations as a service provider of integrated care management and disease management. Castleman is also a Director of USMD Holdings,Inc and a Senior Advisor to McNally Capital LLC in Chicago. Castleman serves as a Director of FemPartners, Inc., and a Senior Advisor to Match Point Partners LLC in New York.
Previously, he held positions as chairman of Mela Sciences, Inc., Director of Med Direct, Inc., President of the Scripps Clinic, President of Caremark International’s Physician Resource Group, and Chief Executive Officer of the Kelsey-Seybold Clinic.
Prior to that Castleman was the Head of the Houston office of Booz Allen & Hamilton (now Booz & Co.).
Castleman received a BA in economics from Yale University and attended New York University Graduate School of Business Administration. He has published articles on management issues in business and technical periodicals, including the Harvard Business Review, and has presented numerous papers and presentations to industry groups in energy, banking, healthcare, and agribusiness.
What is Breaux Castleman's net worth?
The estimated net worth of Breaux Castleman is at least $747,935.10 as of June 25th, 2020. Mr. Castleman owns 25,183 shares of Ionis Pharmaceuticals stock worth more than $747,935 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Castleman may own. Learn More about Breaux Castleman's net worth.
How do I contact Breaux Castleman?
The corporate mailing address for Mr. Castleman and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at wwalke@ionisph.com. Learn More on Breaux Castleman's contact information.
Has Breaux Castleman been buying or selling shares of Ionis Pharmaceuticals?
Breaux Castleman has not been actively trading shares of Ionis Pharmaceuticals in the last ninety days. Most recently, Breaux Castleman sold 10,000 shares of the business's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $60.00, for a transaction totalling $600,000.00. Following the completion of the sale, the director now directly owns 25,183 shares of the company's stock, valued at $1,510,980. Learn More on Breaux Castleman's trading history.
Who are Ionis Pharmaceuticals' active insiders?
Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Michael Hayden (Director), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?
During the last year, Ionis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $181,100.00. During the last year, insiders at the sold shares 18 times. They sold a total of 141,263 shares worth more than $4,915,939.91. The most recent insider tranaction occured on April, 16th when EVP Brian Birchler sold 680 shares worth more than $19,291.60. Insiders at Ionis Pharmaceuticals own 2.7% of the company.
Learn More about insider trades at Ionis Pharmaceuticals. Information on this page was last updated on 4/16/2025.
